Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy
Open Access
- 15 October 2011
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 61 (4) , 535-547
Abstract
Attenuated and heat-killed mycobacteria display demonstrable activity against cancer in the clinic; however, the induced immune response is poorly characterised and potential biomarkers of response ill-defined. We investigated whether three mycobacterial preparations currently used in the clinic (BCG and heat-killed Mycobacterium vaccae and Mycobacterium obuense) can stimulate anti-tumour effector responses in human γδ T-cells. γδ T-cell responses were characterised by measuring cytokine production, expression of granzyme B and cytotoxicity against tumour target cells. Results show that γδ T-cells are activated by these mycobacterial preparations, as indicated by upregulation of activation marker expression and proliferation. Activated γδ T-cells display enhanced effector responses, as shown by upregulated granzyme B expression, production of the TH1 cytokines IFN-γ and TNF-α, and enhanced degranulation in response to susceptible and zoledronic acid-treated resistant tumour cells. Moreover, γδ T-cell activation is induced by IL-12, IL-1β and TNF-α from circulating type 1 myeloid dendritic cells (DCs), but not from type 2 myeloid DCs or plasmacytoid DCs. Taken together, we show that BCG, M. vaccae and M. obuense induce γδ T-cell anti-tumour effector responses indirectly via a specific subset of circulating DCs and suggest a mechanism for the potential immunotherapeutic effects of BCG, M. vaccae and M. obuense in cancer.Keywords
This publication has 48 references indexed in Scilit:
- Nomenclature of monocytes and dendritic cells in bloodBlood, 2010
- Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosisTherapeutics and Clinical Risk Management, 2010
- Isopentenyl Pyrophosphate–Activated CD56+ γδ T Lymphocytes Display Potent Antitumor Activity toward Human Squamous Cell CarcinomaClinical Cancer Research, 2008
- Lysis of a Broad Range of Epithelial Tumour Cells by Human γδ T Cells: Involvement of NKG2D ligands and T‐cell Receptor‐ versus NKG2D‐dependent RecognitionScandinavian Journal of Immunology, 2007
- Interferon-γ induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factorsOncogene, 2006
- SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III resultsAnnals of Oncology, 2004
- γδ T Cells Provide an Early Source of Interferon γ in Tumor ImmunityJournal of Experimental Medicine, 2003
- γδ T cells for immune therapy of patients with lymphoid malignanciesBlood, 2003
- Regulation of Cutaneous Malignancy by γδ T CellsScience, 2001
- Specific Activation of Human Peripheral Blood γ/δ+ T Lymphocytes by Sonicated Antigens of Mycobacterium tuberculosis: Role In Vitro in Killing Human Bladder Carcinoma Cell LinesScandinavian Journal of Immunology, 1993